US and Europe move on Sonus' Echogen:
This article was originally published in Clinica
Executive Summary
Sonus will meet the US FDA on April 27 for further discussions aimed at obtaining marketing approval for its Echogen ultrasound contrast emulsion, following the agency's demand last month for further analysis of trial data. The European Union drugs evaluation committee, the CPMP, reviews the European marketing application for Echogen on March 23.